Latest news and press releases about Moderna, Inc. (MRNA): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Moderna, Inc., a biotechnology firm, is dedicated to the discovery, development, and commercialization of messenger RNA (mRNA) based therapies and preventive medicines. Its extensive research and development efforts target a broad spectrum of medical needs, including infectious diseases, cancer immunology, rare conditions, cardiovascular ailments, and autoimmune disorders, with operations spanning the United States, Europe, and other global markets.
Price
| Price | $203.21 |
| Market Cap | $80.6B |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 11.13 |
| EV / EBITDA | -26.50 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -39.20% |
| Return on Invested Capital | -39.16% |
| Return on Assets | -28.75% |
| Gross Margin | -12.57% |
| Operating Margin | -149.01% |
| Net Margin | -141.43% |
Related companies: BBIO · BMRN · CAI · EXEL · HALO · JAZZ · MDGL
Explore sector: Healthcare · Biotechnology
More sections of MRNA: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Investment Academy — learn to analyze stocks